日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A multicentre demonstration project to evaluate the effectiveness and acceptability of the web-based Joint Asia Diabetes Evaluation (JADE) programme with or without nurse support in Chinese patients with Type 2 diabetes

一项多中心示范项目,旨在评估基于网络的亚洲糖尿病联合评估(JADE)项目在有或无护士支持的情况下,对中国2型糖尿病患者的有效性和接受度。

Tutino, G E; Yang, W Y; Li, X; Li, W H; Zhang, Y Y; Guo, X H; Luk, A O; Yeung, R O P; Yin, J M; Ozaki, R; So, W Y; Ma, R C W; Ji, L N; Kong, A P S; Weng, J P; Ko, G T C; Jia, W P; Chan, J C N

Maternal history of diabetes is associated with increased cardiometabolic risk in Chinese

中国女性母亲有糖尿病史与心血管代谢风险增加相关。

Tam, C H T; Wang, Y; Luan, J; Lee, H M; Luk, A O Y; Tutino, G E; Tong, P C Y; Kong, A P S; So, W Y; Chan, J C N; Ma, R C W

Genome-wide association study in a Chinese population identifies a susceptibility locus for type 2 diabetes at 7q32 near PAX4

一项针对中国人群的全基因组关联研究发现,位于 7q32 区域、靠近 PAX4 基因的位点是 2 型糖尿病的易感基因位点。

Ma, R C W; Hu, C; Tam, C H; Zhang, R; Kwan, P; Leung, T F; Thomas, G N; Go, M J; Hara, K; Sim, X; Ho, J S K; Wang, C; Li, H; Lu, L; Wang, Y; Li, J W; Wang, Y; Lam, V K L; Wang, J; Yu, W; Kim, Y J; Ng, D P; Fujita, H; Panoutsopoulou, K; Day-Williams, A G; Lee, H M; Ng, A C W; Fang, Y-J; Kong, A P S; Jiang, F; Ma, X; Hou, X; Tang, S; Lu, J; Yamauchi, T; Tsui, S K W; Woo, J; Leung, P C; Zhang, X; Tang, N L S; Sy, H Y; Liu, J; Wong, T Y; Lee, J Y; Maeda, S; Xu, G; Cherny, S S; Chan, T F; Ng, M C Y; Xiang, K; Morris, A P; Keildson, S; Hu, R; Ji, L; Lin, X; Cho, Y S; Kadowaki, T; Tai, E S; Zeggini, E; McCarthy, M I; Hon, K L; Baum, L; Tomlinson, B; So, W Y; Bao, Y; Chan, J C N; Jia, W

Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes

在糖尿病小鼠模型中,通过药物降低非酯化脂肪酸(NEFA)水平,可恢复β细胞内GLP-1受体信号通路介导的肠促胰岛素疗法的疗效。

Kang, Z F; Deng, Y; Zhou, Y; Fan, R R; Chan, J C N; Laybutt, D R; Luzuriaga, J; Xu, G

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study

奥美沙坦对伴有明显肾病的2型糖尿病患者肾脏和心血管结局的影响:一项多中心、随机、安慰剂对照研究

Imai, E; Chan, J C N; Ito, S; Yamasaki, T; Kobayashi, F; Haneda, M; Makino, H

Risk-factor profile, drug usage and cardiovascular events within a year in patients with and at high risk of atherothrombosis recruited from Asia as compared with those recruited from non-Asian regions: a substudy of the REduction of Atherothrombosis for Continued Health (REACH) registry

本研究比较了来自亚洲的动脉粥样硬化血栓形成患者和高危患者与来自非亚洲地区的患者的危险因素特征、药物使用情况以及一年内的心血管事件:一项基于“减少动脉粥样硬化血栓形成以促进持续健康”(REACH)注册研究的子研究。

Goto, S; Ikeda, Y; Chan, J C N; Wilson, P W F; Yeo, T Cheng; Liau, C S; Abola, M T; Salette, G; Steg, P G; Bhatt, D L

Pancreatic islet beta-cell deficit and glucose intolerance in rats with uninephrectomy

单侧肾切除大鼠的胰岛β细胞缺陷和葡萄糖耐受不良

Sui, Y; Zhao, H-L; Ma, R C W; Ho, C S; Kong, A P S; Lai, F M M; Ng, H K; Rowlands, D K; Chan, J C N; Tong, P C Y

Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy.

型糖尿病肾病患者细胞因子和丝裂原活化蛋白激酶的异常激活谱

Wong C K, Ho A W Y, Tong P C Y, Yeung C Y, Kong A P S, Lun S W M, Chan J C N, Lam C W K